NASDAQ:CYNA

CYNA (CYNA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$40.48
$40.48
50-Day Range
N/A
52-Week Range
$10.54
$40.67
Volume
N/A
Average Volume
113,889 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYNA stock logo

About CYNA Stock (NASDAQ:CYNA)

Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.

CYNA Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Juanita Mary Martha 'Corky' (Corbett) Swartout
Troy Police Department blotter
Ababa pounds out superb 69, leads by 4
See More Headlines
Receive CYNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CYNA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2016
Today
4/23/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CYNA
Previous Symbol
OTCMKTS:CYNAF
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

CYNA Stock Analysis - Frequently Asked Questions

How were CYNA's earnings last quarter?

CYNA (NASDAQ:CYNA) posted its earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.83) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by $0.06.

What other stocks do shareholders of CYNA own?
When did CYNA IPO?

CYNA (CYNA) raised $64 million in an initial public offering on Thursday, June 18th 2015. The company issued 4,500,000 shares at a price of $14.18 per share. BofA Merrill Lynch acted as the underwriter for the IPO and Nomura and Noble Life Science Partners were co-managers.

This page (NASDAQ:CYNA) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners